Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6235 posts found.

FDA grants ODD to Candel Therapeutics’ pancreatic cancer treatment

April 15, 2024 Medical Communications Candel Therapeutics, FDA, ODD, Oncology, Pancreatic cancer

Candel Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CAN-2409, …
News

Baxter expands US portfolio with new injectables

April 12, 2024 Medical Communications Pharmacy, baxter, injectables, product launch

Baxter International has announced the continued expansion of its pharmaceuticals portfolio with the launch of five new injectable products in …
News

NICE recommends migraine treatment for NHS use

April 11, 2024 Medical Communications NHS, NICE, Neurology, migraine

The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s Aquipta (atogepant) as an option …
News

Gilead’s Veklury recommended by NICE for COVID-19 treatment

April 9, 2024 Medical Communications COVID-19, Gilead Sciences, Infections and infestations, remdesivir

Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has recommended the use of Veklury …
News

FDA accepts UCB’s sBLA for Bimzelx

April 5, 2024 Medical Communications Bimzelx, FDA, Pharmacy, UCB, sBLA

UCB has announced that the US Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application …
News

FDA approves Basilea’s antibiotic Zevtera for three indications

April 4, 2024 Medical Communications Basilea Pharmaceutica, FDA, Infections and infestations, Zevtera, antibiotic

Basilea Pharmaceutica has announced that the US Food and Drug Administration (FDA) has approved Zevtera (ceftobiprole medocaril sodium for injection), …
News

FDA approves Eko Health’s AI for heart failure detection

April 3, 2024 Medical Communications Cardiology, Eko Health, FDA, heart failure, low ejection fraction

Eko Health has announced that the US Food and Drug Administration (FDA) has approved its Low Ejection Fraction (Low EF) …
News

FDA approves Merck’s Winrevair for PAH treatment

March 27, 2024 Medical Communications Cardiology, FDA, Merck, Winrevair, pulmonary arterial hypertension

Merck, known as MSD outside of the US and Canada, has announced that the US Food and Drug Administration (FDA) …
News

FDA approves AstraZeneca’s Ultomiris for NMOSD treatment

March 25, 2024 Medical Communications AstraZeneca, FDA, Neurology, Ultomiris, neuromyelitis optica spectrum disorder

AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvs) as the first and only …
News

FDA approves J&J’s Opsynvi for PAH treatment

March 25, 2024 Medical Communications Cardiology, FDA, J&J, Johnson & Johnson, Opsynvi, pulmonary arterial hypertension

Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has approved Opsynvi (macitentan and tadalafil) …
News

FDA approves Idorsia’s Tryvio for treatment of high blood pressure

March 22, 2024 Medical Communications Cardiology, FDA, Tryvio, blood pressure, blood presure, hypertension

Idorsia has announced that the US Food and Drug Administration (FDA) has approved Tryvio (aprocitentan) for the treatment of hypertension …
News

CHMP recommends Novo Nordisk’s Awiqli for diabetes treatment

March 22, 2024 Medical Communications CHMP, Diabetes, Novo Nordisk, diabetes

Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended …
News
robina-weermeijer-ihfopazzjhm-unsplash_5

MHRA approves Takeda’s Hyqvia for chronic inflammatory demyelinating polyneuropathy treatment

March 21, 2024 Medical Communications Hyqvia, MHRA, Neurology, Takeda, chronic inflammatory demyelinating polyneuropathy

Takeda has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation to Hyqvia as a …
News

Boehringer Ingelheim’s Spevigo gains additional approvals in US and China

March 20, 2024 Medical Communications Boehringer Ingelheim, Dermatology, FDA, Spevigo, psoriasis

Boehringer Ingelheim has announced that Spevigo (spesolimab-sbzo) has been approved by the US Food and Drug Administration (FDA) for the …
News

FDA approves first treatment for liver scarring due to fatty liver disease

March 15, 2024 Medical Communications Endocrinology, FDA, fatty liver disease, liver scarring, nash

The US Food and Drug Administration (FDA) has announced that it has approved Rezdiffra (resmetirom) for the treatment of adult …
News

Latest content

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024

Intra-Cellular Therapies shares phase 3 results for major depressive disorder therapy

April 17, 2024

Novartis shares new data about Fabhalta for IgAN treatment

April 16, 2024